The road to breast cancer screening with diffusion MRI

Abstract

Breast cancer is the leading cause of cancer in women with a huge medical, social and economic impact. Mammography (MMG) has been the gold standard method until now because it is relatively inexpensive and widely available. However, MMG suffers from certain limitations, such as exposure to X-rays and difficulty of interpretation in dense breasts. Among other imaging methods, MRI has clearly the highest sensitivity and specificity, and breast MRI is the gold standard for the investigation and management of suspicious lesions revealed by MMG. Despite this performance, MRI, which does not rely on X-rays, is not used for screening except for a well-defined category of women at risk, because of its high cost and limited availability. In addition, the standard approach to breast MRI relies on Dynamic Contrast Enhanced (DCE) MRI with the injection of Gadolinium based contrast agents (GBCA), which have their own contraindications and can lead to deposit of gadolinium in tissues, including the brain, when examinations are repeated. On the other hand, diffusion MRI of breast, which provides information on tissue microstructure and tumor perfusion without the use of contrast agents, has been shown to offer higher specificity than DCE MRI with similar sensitivity, superior to MMG. Diffusion MRI thus appears to be a promising alternative approach to breast cancer screening, with the primary goal of eliminating with a very high probability the existence of a life-threatening lesion. To achieve this goal, it is first necessary to standardize the protocols for acquisition and analysis of diffusion MRI data, which have been found to vary largely in the literature. Second, the accessibility and cost-effectiveness of MRI examinations must be significantly improved, which may become possible with the development of dedicated low-field MRI units for breast cancer screening. In this article, we will first review the principles and current status of diffusion MRI, comparing its clinical performance with MMG and DCE MRI. We will then look at how breast diffusion MRI could be implemented and standardized to optimize accuracy of results. Finally, we will discuss how a dedicated, low-cost prototype of breast MRI system could be implemented and introduced to the healthcare market.

Cystic Fibrosis and Cancer: Unraveling the Complex Role of CFTR Gene in Cancer Susceptibility

“…CF-related lung disease can make it difficult for patients to undergo mammography due to positioning and breathing difficulties. In such cases, alternative imaging modalities such as breast ultrasound or magnetic resonance imaging (MRI) may be considered [88]. Collaborating with healthcare providers experienced in managing breast cancer screening in individuals with CF can help develop appropriate and effective screening strategies.…”

Development and validation of an ultrasonography and clinicopathological features-based nomogram for non-sentinel lymph node metastasis

“…Also, the experimental results that were reported by Fu et al ( 19 ) indicated that magnetic resonance imaging (MRI) is worthy of clinical promotion and usage, based on its ability to diagnose the ALN metastasis of BC. However, MRI was limited by factors such as high sensitivity and costs, low specificity, and the long time for preliminary diagnosis ( 20 ), so its diagnostic value was not discussed in this study. Therefore, an NSLNM risk prediction model based on the Chinese population needs to be developed to further guide clinical treatment.…”

Editorial for “Deep Learning k‐Space‐to‐Image Reconstruction Facilitates High Spatial Resolution and Scan Time Reduction in Diffusion‐Weighted Imaging BreastMRI”

“…While forthcoming prospective studies may present difficulties in comparisons due to a lack of reference standards, they are anticipated to demonstrate superior efficacy. Additionally, using DLSR on data with higher acquired spatial resolution by maintaining current scan durations, there is potential to detect smaller, early‐stage breast cancers with greater accuracy, thereby potentially reestablishing DWI as a more reliable screening tool 7 . This anticipated shift could significantly fortify the array of non‐invasive diagnostic approaches in the battle against breast cancer, leveraging the inherent capabilities of DWI in clinical application.…”